slot88 slot online cincinbet situs slot gacor cincinbet usaklub slot gacor hari ini

Open Access Mini Review

LRRK2 Signalling Pathways in Parkinson’s Disease

Jinwei Zhang*

Institute of Biomedical and Clinical Sciences, College of Medicine and Health, University of Exeter, Hatherly Laboratories, Exeter, EX4 4PS, UK

Corresponding Author

Received Date:January 08, 2019;  Published Date: January 16, 2019


Parkinson’s disease (PD) is a common neurodegenerative disorder with the pathological hallmark of progressive loss of dopamine neurons in affected brains. There is no cure for PD and current therapy does not halt the underlying degenerative process. The pathogenesis of PD is not fully understood but is likely caused by a combination of genetic and environmental factors. Several genes are associated with the onset and progression of familial PD. Mutations in LRRK2 are the most frequent known cause of lateonset PD. Many studies have been conducted to elucidate the functions of LRRK2 and identify effective LRRK2 inhibitors for PD treatment. In this review, I discuss the role of LRRK2 in PD and recent progress in studying LRRK2 cellular functions and the use of LRRK2 inhibitors as therapeutic agents.

Signup for Newsletter
Scroll to Top